Abstract
Deferasirox is an FDA-approved iron chelator used in the treatment of iron toxicity. In this work, we report the use of several deferasirox derivatives as lanthanide chelators. Solid-state structural studies of three representative trivalent lanthanide cations, La(III), Eu(III), and Lu(III), revealed the formation of 2:2 complexes in the solid state. A 1:1 stoichiometry dominates in DMSO solution, with Ka values of 472 ± 14, 477 ± 11, and 496 ± 15 M-1 being obtained in the case of these three cations, respectively. Under the conditions of competitive precipitation in the presence of triethylamine, high selectivity (up to 80%) for lutetium(III) was observed in competition with La(III), Ce(III), and Eu(III). Theoretical calculations provided support for the observed selective crystallization.
Cite
CITATION STYLE
Mangel, D. N., Juarez, G. J., Carpenter, S. H., Steinbrueck, A., Lynch, V. M., Yang, J., … Sessler, J. L. (2023). Deferasirox Derivatives: Ligands for the Lanthanide Series. Journal of the American Chemical Society, 145(40), 22206–22212. https://doi.org/10.1021/jacs.3c08375
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.